Chemotherapy and G-CSF for Mobilization
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Multiple Myeloma
Related studies linked through entity extraction aliases.
ECT-001 (UM171) Expanded Cord Blood Transplant to Treat High-risk Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Pom-dex Versus Pom-Cyclo-dex in MM Patients With Biochemical or Clinical Relapse, During Lena Maintenance Treatment
- Status
- TERMINATED
- Phase
- PHASE3
A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product
- Status
- TERMINATED
- Phase
- N/A
Chemokine Receptor CXCR4-targeting Molecular Imaging for Metabolic Characterization of Multiple Myeloma and Lymphoma
- Status
- UNKNOWN
- Phase
- EARLY_PHASE1
Monitoring of Deep of Response During Lenalidomide Maintenance in MM Patients Achieving at Least Very Good Partial Response (MRD)
- Status
- COMPLETED
- Phase
- N/A
Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Multiple Myeloma Molecular Monitoring Study
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
Len/Dex/DLI in Relapsed Multiple Myeloma After Allogeneic Stem Cell Transplant
- Status
- COMPLETED
- Phase
- PHASE2
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens
- Status
- COMPLETED
- Phase
- PHASE2
Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide
- Status
- TERMINATED
- Phase
- PHASE2
Validation of a Personalised Medicine Tool for Multiple Myeloma That Predicts Treatment Effectiveness in Patients
- Status
- COMPLETED
- Phase
- N/A
Detection of Poor Mobilizer (PM) in Multiple Myeloma (MM) Patients
- Status
- COMPLETED
- Phase
- N/A
Validation of the 4TS RAM in the Prevention of Venous Thromboembolism in Patients With Plasma Cell Dyscrasias.
- Status
- UNKNOWN
- Phase
- N/A
Superiority of VCD Versus CTD in Patients With Newly Diagnose Multiple Myeloma Eligible for Transplantation
- Status
- COMPLETED
- Phase
- PHASE3
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
- Status
- TERMINATED
- Phase
- PHASE1